In order to help move the Immunoscore assay into the clinic and ultimately to benefit patients with cancer, SITC is pleased to announce a Key Information Release from the SITC Immunoscore Validation Project. Under this release, key information concerning the detailed methodology used to calculate the Immunoscore will be shared to qualified entities upon request. To learn more about the Key Information Release, review criteria, and application process, please visit here. Information Request Forms will be accepted until July 5, 2016.
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients
June 05, 2016 – Chicago, IL
The latest results from the Immunoscore project were presented by Dr. Jérôme Galon during the Oral Abstract Session at the 2016 ASCO Annual Meeting. To view the SITC press release and updated results, visit here.
The outcome prediction in cancer is usually achieved by evaluating tissue samples obtained during surgical removal of the primary tumor and focusing on their histopathological characteristics. Tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N), and evidence for metastases (M). However, it is recognized that cancer outcomes can vary significantly among patients within the same stage. This classification provides limited prognostic information in estimating the outcome in cancer and does not predict response to therapy.
Recently, many reports suggest that cancer development is controlled by the host’s immune system, underlying the importance of including immunological biomarkers for the prediction of prognosis and response to therapy, a concept that has been termed “immunoscore”. Data collected from large cohorts of human cancers demonstrated that the immune-classification has a prognostic value that may add significantly to the AJCC/UICC TNM-classification. Thus, it is imperative to begin incorporating immune scoring as a prognostic factor and to introduce this parameter as a marker to classify cancers, as part of the routine diagnostic and prognostic assessment of tumors. At the same time, the inherent complexity of quantitative immunohistochemistry, in conjunction with variable assay protocols across laboratories, the different immune cell types analyzed, different region selection criteria, and variable ways to quantify immune infiltration underscore the urgent need to reach assay harmonization.
In an effort to promote the immunoscore in routine clinical settings, the SITC Immunoscore Validation Project was initiated with 23 centers in 17 countries worldwide. This project was organized through collaborations with the European Academy of Tumor Immunology; the Cancer and Inflammation Program; the National Cancer Institute, National Institutes of Health, USA; and La Fondazione Melanoma. The results of this global validation project may result in the implementation of the immunoscore as a new component for the classification of cancer.
Jérôme Galon, PhD - INSERM, Cordeliers Research Center, Paris, France
Franck Pagès, MD, PhD - Immunomonitoring plateform, Georges Pompidou European Hospital, Paris, France
INSERM, Cordeliers Research Center, Paris, France
Melanoma Bridge 2015
December 1-4, 2015 – Naples, Italy
World-Wide Immunoscore Task Force: an Update
For more information, visit here.
Immunoscore Update Session at the STIC 30th Annual Meeting
November 7, 2015 – National Harbor, MD
View video and presentation slides from this program here.
Immunoscore Slide Sharing Portal kick-off call and PathForceDx online training session
August 13, 2014
Participating Centers from across Europe, Asia, and North America met online to explore PathForceDx software functions and to discuss ideas and best practices for sharing slides and data.
Natural and Therapy-induced Anticancer Immunosurveillance: The Immunoscore
July 3-4th 2014 – Paris, France
World Immunoscoring Meeting
December 4th 2012 – Naples, Italy
Supported by SITC, Melanoma Foundation and EATI
This initiative has been made possible by the generous support of the following companies:
Slide-sharing portal powered by PathForceDX.